PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33019464-4 2020 CONCLUSION: Celecoxib mainly regulates the proliferation, migration, and invasion of tumor cells by inhibiting the cyclooxygenases-2/prostaglandin E2 signal axis and thereby inhibiting the phosphorylation of nuclear factor-kappa-gene binding, Akt, signal transducer and activator of transcription and the expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. Celecoxib 12-21 matrix metallopeptidase 2 Homo sapiens 319-345 18438340-17 2008 There were significant differences in the MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in the group H but not in L and M groups. Celecoxib 96-105 matrix metallopeptidase 2 Homo sapiens 155-160 17404023-7 2007 In addition, 10 uM celecoxib inhibited cell invasion/migration through the type I collagen matrix by approximately 40% within 24 h. The results of zymography reveal that, in the presence of 10 muL celecoxib, both MMP-2 and MMP-9 enzyme activity decreased by approximately 30-40%. Celecoxib 19-28 matrix metallopeptidase 2 Homo sapiens 213-218 17404023-7 2007 In addition, 10 uM celecoxib inhibited cell invasion/migration through the type I collagen matrix by approximately 40% within 24 h. The results of zymography reveal that, in the presence of 10 muL celecoxib, both MMP-2 and MMP-9 enzyme activity decreased by approximately 30-40%. Celecoxib 197-206 matrix metallopeptidase 2 Homo sapiens 213-218 16253161-3 2005 Moreover, cells were stimulated by hypoxia or celecoxib or both of them, prostaglandin E(2) (PGE(2)), matrix metalloproteinase 2, 9 (MMP-2, MMP-9) release was detected by enzyme-linked immunosorbent assay (ELISA) or gelatin zymography. Celecoxib 46-55 matrix metallopeptidase 2 Homo sapiens 102-131 16253161-9 2005 (4) The amount of MMP-2, MMP-9 produced by synovial fibroblasts under 12 h hypoxic condition was upregulated compared with that under normoxia or in response to celecoxib combined with hypoxia. Celecoxib 161-170 matrix metallopeptidase 2 Homo sapiens 18-23 17313803-8 2006 The grey level of MMP-2 and MMP-9 in the combination and celecoxib groups were (99 +/- 20, 89 +/- 13) and (260 +/- 15, 180 +/- 13) respectively, both significantly lower than that of the control group [(314 +/- 11, 241 +/- 12), P < 0.05]. Celecoxib 57-66 matrix metallopeptidase 2 Homo sapiens 18-23 32994805-8 2020 In addition, celecoxib alone or in combination with aspirin inhibited the migration and invasion of NSCLC cells by inhibiting MMP-9 and MMP-2 activity levels. Celecoxib 13-22 matrix metallopeptidase 2 Homo sapiens 136-141 24640603-0 2014 Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Celecoxib 27-36 matrix metallopeptidase 2 Homo sapiens 132-165 27430377-8 2016 Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells. Celecoxib 0-9 matrix metallopeptidase 2 Homo sapiens 73-78 30127823-7 2018 Real time PCR results showed that both CX (5 microM) and VPA (2.5 and 5 mM) reduced MMP-2 expression (P < 0.05) but had no significant effects on the expression of MMP-9. Celecoxib 39-41 matrix metallopeptidase 2 Homo sapiens 84-89 26592832-5 2015 Western blot analysis was used to detect the protein expression of RECK, matrix metalloproteinase (MMP)-2 and MMP-9 in celecoxib-treated MG-63 cells. Celecoxib 119-128 matrix metallopeptidase 2 Homo sapiens 73-105 26592832-10 2015 Western blot analyses revealed that the expression of MMP-2 and MMP-9 was markedly down-regulated but RECK, an inhibitor of MMPs, was markedly up-regulated in MG-63 cells exposed to 20 microg/ml celecoxib for 24 or 48h. Celecoxib 195-204 matrix metallopeptidase 2 Homo sapiens 54-59 26592832-10 2015 Western blot analyses revealed that the expression of MMP-2 and MMP-9 was markedly down-regulated but RECK, an inhibitor of MMPs, was markedly up-regulated in MG-63 cells exposed to 20 microg/ml celecoxib for 24 or 48h. Celecoxib 195-204 matrix metallopeptidase 2 Homo sapiens 124-128 26592832-13 2015 Celecoxib-induced down-regulation of MMP-2 and MMP-9 and up-regulation of RECK may contribute to the apoptosis induction and an alteration in local tumor microenvironment. Celecoxib 0-9 matrix metallopeptidase 2 Homo sapiens 37-42 26592832-14 2015 These findings suggest that celecoxib may exert at least in part of its anticancer effects via up-regulation of RECK to inhibit the expression of MMP-2 and MMP-9. Celecoxib 28-37 matrix metallopeptidase 2 Homo sapiens 146-151 24640603-9 2014 Celecoxib had a significant inhibitory effect on the activity of MMP-2/9 in a dose-dependent manner in HNE1, HONE1 and SUNE1-5-8F cell lines. Celecoxib 0-9 matrix metallopeptidase 2 Homo sapiens 65-72 24640603-10 2014 These data demonstrated that celecoxib-induced suppression of MMP-2 and MMP-9 activity might be involved in the inhibition of nasopharyngeal carcinoma cell lines invasion and migration. Celecoxib 29-38 matrix metallopeptidase 2 Homo sapiens 62-67 22497997-5 2012 We found that co-incubation of Colo357 with celecoxib and EGCG synergistically diminished metabolic activity via apoptosis induction and down-regulated release of pro-angiogenic vascular endothelial growth factor (VEGF) and invasiveness-promoting matrix metalloproteinase (MMP)-2 to a maximum of 30%. Celecoxib 44-53 matrix metallopeptidase 2 Homo sapiens 247-279 21540248-9 2011 Moreover, celecoxib significantly decreased Cox-2, MMP-2 and PGE2 expression and inhibited invasion/migration activity in As(2)O(3)-treated cells (P < 0.05), indicating that As(2)O(3) inhibits invasion/migration by regulating the expression of Cox-2/PGE2/MMP-2. Celecoxib 10-19 matrix metallopeptidase 2 Homo sapiens 51-56 21540248-9 2011 Moreover, celecoxib significantly decreased Cox-2, MMP-2 and PGE2 expression and inhibited invasion/migration activity in As(2)O(3)-treated cells (P < 0.05), indicating that As(2)O(3) inhibits invasion/migration by regulating the expression of Cox-2/PGE2/MMP-2. Celecoxib 10-19 matrix metallopeptidase 2 Homo sapiens 253-263 21365830-6 2010 Celecoxib could decrease the expression of Cox-2 protein in Tca8113 cell and decrease the MMP-2 level in supernatant. Celecoxib 0-9 matrix metallopeptidase 2 Homo sapiens 90-95 20709621-0 2010 Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. Celecoxib 21-30 matrix metallopeptidase 2 Homo sapiens 148-153 20709621-3 2010 Our study observed the inhibitive effect of selective COX-2 inhibitor, celecoxib, on adhesion and invasion ability of human tongue squamous carcinoma cell line Tca8113 and its relationship with MMP-2 secretion. Celecoxib 71-80 matrix metallopeptidase 2 Homo sapiens 194-199 20709621-9 2010 Celecoxib could inhibit PGE2 production of Tca8113 cell in a dose-dependent manner, down-regulate MMP-2 secretion of Tca8113 cell, and at the same time significantly inhibit invasion and adhesion ability of these cells. Celecoxib 0-9 matrix metallopeptidase 2 Homo sapiens 98-103 20709621-10 2010 Adding extrinsic PGE2 could antagonize the inhibitive effect of celecoxib not only on MMP-2 secretion of Tca8113 cell, but also on invasion and adhesion ability of the cells. Celecoxib 64-73 matrix metallopeptidase 2 Homo sapiens 86-91